{"denoms":[{"counts":[{"groupId":"BG000","value":"442"},{"groupId":"BG001","value":"444"},{"groupId":"BG002","value":"886"}],"units":"Participants"}],"groups":[{"description":"Participants received enfortumab vedotin at 1.25 mg/kg as an IV infusion over approximately 30 minutes on Days 1 and 8 of each cycle, and pembrolizumab 200 mg as an IV infusion over approximately 30 minutes on Day 1 of each cycle, after completion of the enfortumab vedotin infusion. 1 cycle = 3 weeks.","id":"BG000","title":"Enfortumab Vedotin + Pembrolizumab"},{"description":"Participants received gemcitabine at 1000 mg/m\\^2 as an IV infusion on Days 1 and 8 of each cycle, and either cisplatin (70 mg/m\\^2) or carboplatin (AUC 4.5, or AUC 5 according to local guidelines) on Day 1 of each cycle, with adequate pre- and post-hydration, by IV infusion per institutional standards. 1 cycle = 3 weeks.","id":"BG001","title":"Standard of Care"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.1","value":"67.9"},{"groupId":"BG001","spread":"9.4","value":"68.0"},{"groupId":"BG002","spread":"9.2","value":"67.9"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"98"},{"groupId":"BG001","value":"108"},{"groupId":"BG002","value":"206"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"344"},{"groupId":"BG001","value":"336"},{"groupId":"BG002","value":"680"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"52"},{"groupId":"BG002","value":"104"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"359"},{"groupId":"BG001","value":"343"},{"groupId":"BG002","value":"702"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"31"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"80"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"99"},{"groupId":"BG001","value":"92"},{"groupId":"BG002","value":"191"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"10"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"308"},{"groupId":"BG001","value":"290"},{"groupId":"BG002","value":"598"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"Other"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"}],"title":"Multiple"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"15"}],"title":"Unknown"},{"measurements":[{"groupId":"BG000","value":"22"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"59"}],"title":"Not Reported"}],"title":"Race"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}],"populationDescription":"Intent-to-Treat (ITT) analysis set include all randomized participants. Participants were analyzed according to the treatment arm assigned at randomization regardless of the actual treatment received."}